We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

2026 EMPLOYER SURVEY DATA

Employer GLP-1 coverage statistics

Read the latest KFF employer coverage figures with dates, denominators and direct links to the underlying report.

Program planning • No employee health data • Final terms confirmed before launch

Employer-funded programBudget around active participation
HSA / FSA optionsCheck eligibility and documentation
A clear coverage pathwayKeep insurance and care decisions separate

QUICK ANSWER

KFF’s 2026 survey found 18% of firms with 200 or more workers covered GLP-1 agonists primarily for weight loss in their largest-enrollment plan. Rates ranged from 16% at firms with 200–999 workers to 33% at firms with 5,000 or more. Every figure below links to the October 22, 2026 report.

Last updated by the Kindr Health team

THE NUMBERS, WITH DENOMINATORS

What does the 2026 KFF survey show?

Every figure: KFF, 2026 Employer Health Benefits Survey, Section 12 and overview. Published October 22, 2026; 1,937 interviews with non-federal public and private firms.

Coverage by employer size

18%

Firms with 200 or more workers covering GLP-1 agonists primarily for weight loss in their largest-enrollment plan.

Overall result; surveyed firms offer health benefits.KFF · October 22, 2026
16%

Coverage among firms with 200–999 workers.

19% of these firms said they did not know whether their plan covered the medicines for weight loss.KFF · October 22, 2026
29%

Coverage among firms with 1,000–4,999 workers.

Firm-size result, not the share of employees covered.KFF · October 22, 2026
33%

Coverage among firms with 5,000 or more workers.

KFF describes the change from 43% in 2025 as similar to 2026; avoid presenting the numerical difference as a proven trend.KFF · October 22, 2026

Requirements and spending

40%

Covering firms requiring a clinical-professional meeting or lifestyle-program participation.

35% among firms with 200–999 workers and 59% among firms with 5,000 or more workers.KFF · October 22, 2026
29%

Covering firms reporting a significant impact on prescription drug spending.

Another 27% reported a moderate impact, 23% minor, 10% none and 11% did not know.KFF · October 22, 2026
61%

Firms with 5,000 or more workers reporting a significant prescription-spending impact among those that cover.

The comparable figure for firms with 200–999 workers was 21%.KFF · October 22, 2026

What changed and what comes next

12%

Non-covering firms with 200 or more workers that stopped coverage within the previous 12 months.

The denominator is firms that do not cover weight-loss GLP-1 agonists in their largest-enrollment plan.KFF · October 22, 2026
1%

Non-covering firms saying they are very likely to begin coverage in the next 12 months.

13% were somewhat likely, 79% not likely and 7% did not know.KFF · October 22, 2026

The wider benefits budget

$28,303

Average annual employer-sponsored family health premium in 2026.

Up 5% from 2025. This is total family coverage, not a GLP-1-specific price.KFF · October 22, 2026
$7,471

Average covered-worker annual contribution toward family coverage.

This is an average across employer-sponsored family coverage, not a GLP-1 copay.KFF · October 22, 2026

A MORE CONNECTED MODEL

How do the three parts fit together?

A practical structure for benefits teams, with a deliberate separation between business and clinical decisions.

01

Coverage varies sharply by firm size

KFF reports different weight-loss GLP-1 coverage rates for firms with 200–999, 1,000–4,999 and 5,000 or more workers.

02

Clinical requirements are common

Among firms that cover the medicines for weight loss, KFF tracks requirements to meet a clinical professional or join a lifestyle program.

03

Read percentages in context

These figures describe surveyed firms offering health benefits and their largest-enrollment plan. They do not describe every employee or every insurance plan.

How should you read the 2026 coverage rate?

KFF asked firms with 200 or more workers offering health benefits about GLP-1 agonists used primarily for weight loss in the plan with their largest enrollment. The overall 18% result is weighted to firms; it is not the percentage of workers whose plans cover the medicines.

The report includes 1,937 interviews with non-federal public and private firms. Coverage was 16% among firms with 200–999 workers, 29% among those with 1,000–4,999 and 33% among those with 5,000 or more. Some respondents answered that they did not know, especially in the smallest of those groups.

What changed from previous surveys?

KFF reports that the overall figure was 19% in 2025 and 18% in 2024, and describes the 2026 overall result as similar to both. It also describes the 33% result among firms with 5,000 or more workers as similar to 43% in 2025. “Similar” reflects the report’s statistical interpretation; do not turn the numerical changes into a claim of a proven rise or fall.

Among firms that did not cover the drugs for weight loss, 12% said they stopped coverage in the preceding 12 months. Only 1% said they were very likely to add it in the next 12 months, while 13% were somewhat likely.

What do the spending figures mean for a budget?

Among covering firms, 29% reported a significant prescription-spending impact, 27% moderate, 23% minor, 10% none and 11% did not know. These are employer-reported impact categories, not measured dollar savings or a common cost per participant.

Use the figures to frame questions for your insurer, PBM and finance team. Do not apply another employer’s experience as a forecast. The $199 Kindr Benefits model is a separate proposed program fee and is not derived from KFF’s data.

How did coverage differ by firm size in 2026?

Firm sizeCover for weight lossImportant context
200–999 workers16%19% did not know their coverage position
1,000–4,999 workers29%Firm-level response for largest-enrollment plan
5,000 or more workers33%43% in 2025; KFF calls results similar
All firms with 200+ workers18%19% in 2025 and 18% in 2024

PRIVACY IS THE BOUNDARY

How is business information kept separate?

Employer and broker information never needs to include an individual’s diagnosis, prescription or clinical notes. Clinical assessment and treatment belong with licensed professionals.

Read our privacy pledge
Business zone

Organization details, proposals and agreed program terms.

Clinical zone

Individual health information and medical decisions stay separate.

Independent decisions

No enrollment guarantee, insurance promise or employer-directed prescribing.

THE DETAILS MATTER

What questions should you ask before moving forward?

What is the source for every number?

Every statistic links to KFF’s 2026 Employer Health Benefits Survey, published October 22, 2026.

Who decides whether an employee gets medication?

A licensed clinician. Employers fund the program but never direct prescribing.

Is medication included in the program fee?

No. Medication is a separate pass-through cost, shown apart from the program fee.

Does HR see who is enrolled in treatment?

No. Reporting is aggregated and limited to groups of 20 or more.

What must be signed before launch?

The MSA, Order Form and Plan Language, countersigned before onboarding.

Can we start with a small group?

Yes. You pay only for active enrolled participants, so cost scales with use.

SOURCES & DATES

Where does this information come from?

We aim to cite the original study or official guidance for every research claim. Kindr Health offers telehealth services discussed on some pages.

YOUR NEXT STEP

Ready to shape your Benefits program?

Begin with your organization, your priorities and a realistic program budget. No employee health information required.